KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Investments (2022 - 2025)

Historic Long-Term Investments for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q3 2025 value amounting to $93.0 million.

  • Xenon Pharmaceuticals' Long-Term Investments fell 3772.44% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year decrease of 3772.44%. This contributed to the annual value of $127.5 million for FY2024, which is 5645.51% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Long-Term Investments is $93.0 million, which was down 3772.44% from $137.3 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Long-Term Investments peaked at $292.8 million during Q4 2023, and registered a low of $93.0 million during Q3 2025.
  • Its 4-year average for Long-Term Investments is $144.9 million, with a median of $129.1 million in 2024.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Long-Term Investments skyrocketed by 12753.14% in 2023 and then tumbled by 5645.51% in 2024.
  • Xenon Pharmaceuticals' Long-Term Investments (Quarter) stood at $128.7 million in 2022, then soared by 127.53% to $292.8 million in 2023, then plummeted by 56.46% to $127.5 million in 2024, then decreased by 27.07% to $93.0 million in 2025.
  • Its Long-Term Investments was $93.0 million in Q3 2025, compared to $137.3 million in Q2 2025 and $141.5 million in Q1 2025.